Tag: Glioblastoma
TME Pharma: news regarding patients with glioblastoma
By Hector Chaunu Published on 04/23/2024 at 08:09 a.m. Photo credit © ChaunuPictures (Boursier.com) — TME Pharma…
TME Pharma: Fast Track designation in glioblastoma – 04/03/2024 at 1:27 p.m.
(CercleFinance.com) – TME Pharma announces that the US FDA has granted Fast Track designation to its NOX-A12, in combination with radiotherapy and bevacizumab, for use in the treatment of aggressive…
Glioblastoma: symptoms, therapy, prognosis
A glioblastoma is a malignant brain tumor known for its rapid growth. Despite intensive treatment with surgery, radiotherapy and chemotherapy, the prognosis is usually poor. How does a glioblastoma manifest…
TME PHARMA PRESENTS CLINICAL UPDATE ON GLORIA EXPANSION ARM TESTING NOX-A12 IN COMBINATION WITH RADIOTHERAPY AND BEVACIZUMAB IN PATIENTS WITH GLIOBLASTOMA – 01/23/2023 at 08:00
• With a median follow-up of 10 months to date, 5 of 6 patients remain alive. • Follow-up continues as median overall survival has not yet been reached. Berlin, Germany,…
NOXXON Presents Key Data from Phase 1/2 GLORIA Study Evaluating NOX-A12 in Glioblastoma at ASCO 2022 Annual Meeting – 06/05/2022 at 15:00
To receive all the news in real time from NOXXON, please contact [email protected] Berlin, Germany, June 5, 2022, 3:00 p.m. CEST – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a…
NOXXON Secures EUR 17 Million Extension Under Funding Agreement with Atlas to Develop NOX-A12 in Glioblastoma and Pancreatic Cancer Programs – 12/29/2021 at 6:00 PM
To receive all Noxxon news in real time, contact [email protected] Berlin, Germany, December 29, 2021, 6:00 p.m. CET – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing…